

**Aryl Radical Cyclizations of
1-(2'-Bromobenzyl)isoquinolines with AIBN-Bu₃SnH:
Formation of Aporphines and Indolo[2,1-*a*]isoquinolines**


Supporting Information

Kazuhiko Orito,* Shiho Uchiito, Yoshitaka Satoh, Takashi Tatsuzawa
Rika Harada, and Masao Tokuda


*Laboratory of Organic Synthesis, Division of Molecular Chemistry,
Graduate School of Engineering, Hokkaido University, Sapporo 060-8628, Japan*

Experimental Procedure for Radical Cyclizations and
Spectral Data for Aporphines and Indolo[2,1-*a*]isoquinolines

General Procedure for Radical Cyclization of 1-(2'-Bromobenzyl)-3,4-dihydroisoquinolines (1a~i, 9, 11a~c, and 13c) and 1-(2'-Bromobenzoyl)-3,4-dihydroisoquinolines (4, 8).¹ A solution of AIBN (66 mg, 0.4 mmol), Bu₃SnH (233 mg, 0.8 mmol) in dry toluene (15 mL) was added in four portions at every 30 min during 1.5 h to a boiling solution of **1b**¹ (162 mg, 0.5 mmol) in dry toluene (15 mL) with stirring under nitrogen in an oil bath at 130°C. After the mixture was heated for an additional 2.5 h, the solvent was evaporated under reduced pressure. ¹H NMR analysis revealed that the residue comprised **2b** and **3b** in 55:45. It was dissolved in CH₃CN (10 mL), and washed with hexane (30 mL × 5). One half of this CH₃CN fraction was subjected to preparative TLC on a Merck silica gel 60 PF₂₅₄ developed with CH₂Cl₂ containing 1% MeOH, followed by crystallization from MeOH-Et₂O, gave indolo[2,1-*a*]isoquinoline **3b** (19 mg, 30%, *R_f* 0.37), mp 195-198 °C. Another one half was dissolved in MeOH (10 mL) containing 3 drops of 2N-NaOH solution, and stirred at rt overnight. The mixture was concentrated, treated with CH₂Cl₂ (10 mL × 2) and water (10 mL). The CH₂Cl₂ layers were washed with saturated brine (10 mL), dried (Na₂SO₄), and concentrated. Separation of the residue in the same manner as the above gave oxoaporphine **2b** (27 mg, 42%, *R_f* 0.89), mp > 300 °C (MeOH-Et₂O).



2,3,8,9-Tetramethoxy-5,6-dihydroindolo[2,1-*a*]isoquinoline (3a): 68%; dark green crystals; mp 193-195 °C (MeOH-Et₂O) (lit.¹ mp 193-195 °C); ¹H NMR (270 MHz, CDCl₃) δ 3.09, 4.63 (each t, *J* = 6.6 Hz, each 2H), 3.92, 3.93, 3.95, 3.97 (each s, each 3H), 6.67, 6.75 (each s, each 1H), 6.81, 7.24 (AB type, *J* = 8.6 Hz, each 1H), 7.18 (s, 1H).




4H-1,2-Dimethoxy-10,11-(methylenedioxy)-5,6-dihydrodibenzo[*de, g*]quinoline (2b):* ¹H NMR (270 MHz, CDCl₃) δ 3.21 (t, *J* = 5.9 Hz, 2H), 3.40 (t, *J* = 5.9 Hz, 2H), 3.72, 3.99 (s, each 3H), 6.07 (s, 2H), 6.54 (s, 1H), 7.05 (s, 1H), 7.09, 7.10 (each s, each 1H).

* The word of "methylenedioxy" is conveniently used for "benzodioxolo" or "dioxolo" through this manuscript.

Oxoaporphine derived from 2b, 1,2-dimethoxy-10,11-(methylenedioxy)-7-oxodibenzo[de, g]quinoline (4b): 42%; yellow crystals; mp > 300 °C (MeOH-Et₂O); IR (Nujol) 1652, 1606, 1576 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.93, 4.08 (s, each 3), 6.20 (s, 2H), 7.06, 8.23 (AB type, *J* = 8.3 Hz, each 1H), 7.19 (s, 1H), 7.75, 8.85 (AB type, *J* = 5.3 Hz, each 1H); EIMS *m/z* (rel. int.) 336 [(M + H)⁺, 4.3], 335 (M⁺, 100), 320 [(M - CH₃), 28.8], 292 (29.2). Anal. Calcd for C₁₉H₁₃NO₅: C, 68.10; H, 3.91; N, 4.18. Found; C, 67.97; H, 4.08; N, 3.95.


2,3-Dimethoxy-8,9-(methylenedioxy)-5,6-dihydroindolo[2,1-a]isoquinoline (3b): 30%; dark green crystals, mp 195-198 °C (MeOH-Et₂O) (lit.¹ 198-200 °C); ¹H NMR (270 MHz, CDCl₃) δ 3.11, 4.39 (each t, *J* = 6.6 Hz, each 2H), 3.91, 3.95 (each s, each 3H), 6.00 (s, 2H), 6.68, 6.74 (each s, each 1H), 6.74, 7.06 (AB type, *J* = 8.6 Hz, each 1H), 7.18 (s, 1H).



4H-10,11-Dimethoxy-1,2-(methylenedioxy)-5,6-dihydrodibenzo[de, g]quinoline (2c): ¹H NMR (270 MHz, CDCl₃) δ 3.20 (t, *J* = 5.6 Hz, 2H), 3.44 (t, *J* = 5.9 Hz, 2H), 3.75, 3.93 (s, each 3H), 6.11 (s, 2H), 6.48 (s, 1H), 6.99 (s, 1H), 7.21 (s, 2H).

Oxoaporphine derived from 2c, 10,11-dimethoxy-1,2-(methylenedioxy)-7-oxodibenzo[de, g]quinoline (4c): 18%; yellow crystals; mp > 300 °C (MeOH-Et₂O) (lit.² mp 240-241 °C); IR 1663, 1638, 1575, 1510 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.81, 4.03 (s, each 3H), 6.26 (s, 2H), 7.17, 8.37 (AB type, *J* = 8.9 Hz, each 1H), 7.18 (s, 1H), 7.72, 8.82 (AB type, *J* = 5.3 Hz, each 1H). EIMS *m/z* (rel. int.) 336 [(M + H)⁺, 25.7], 335 (M⁺, 100), 320 [(M - CH₃)⁺, 48.9], 292 (21.2), 364 (27.7), 221 (24.9). Anal. Calcd for C₁₉H₁₃NO₅: C, 68.10; H, 3.91; N, 4.18. Found; C, 67.85; H, 3.93; N, 4.36.

8,9-Dimethoxy-2,3-(methylenedioxy)-5,6-dihydroindolo[2,1-a]isoquinoline (3c): 52%; gray crystals; mp 180.5-182 (MeOH-Et₂O) (lit.¹ 177-180 °C); ¹H NMR (270 MHz, CDCl₃) δ 3.06, 4.58 (each t, *J* = 6.3 Hz, each 2H), 3.93, 3.96 (each s, each 3H), 6.97 (s, 2H), 6.62, 6.72 (each s, each 1H), 6.80, 7.20 (AB type, *J* = 8.6 Hz, each 1H), 7.19 (s, 1H).




4H-1,2:10,11-Bis(methylenedioxy)-5,6-dihydrodibenzo[de, g]quinoline (2d): ¹H NMR (270 MHz, CDCl₃) δ 3.19, 3.43 (t, *J* = 5.9 Hz, each 2H), 6.07, 6.12 (s, each 2H), 6.53 (s, 1H), 6.97 (s, 1H), 7.06, 7.08 (s, each 1H).

Oxoaporphine derived from 2d, hernandinine (4d): 29%; yellow crystals; mp > 300 °C (MeOH-CHCl₃) (lit.³ mp >280 °C; 4,5 298-300 °C); ¹H NMR (270 MHz, CDCl₃) δ 6.17, 6.25 (s, each each 2H), 7.04, 8.27 (AB type, *J* = 8.6 Hz, each 1H), 7.16 (s, 1H), 7.72, 8.83 (AB type, *J* = 5.3 Hz, each 1H); EI-MS *m/z* (rel. int.) 320 [(M + 1)⁺, 23.2], 319 (M⁺, 100), 175 (12.3).


2,3:8,9-Bis(methylenedioxy)-5,6-dihydroindolo[2,1-a]isoquinoline (3d): 29%; gray crystals; mp 205-206 °C (EtOH) (lit.¹ mp 205-206 °C); ¹H NMR (270 MHz, CDCl₃) δ

3.08, 4.37 (each t, $J = 6.6$ Hz, each 2H), 5.97, 5.99 (each s, each 2H), 6.64, 6.72 (each s, each 1H), 6.75, 7.06 (AB type, $J = 8.3$ Hz, each 1H), 7.16 (s, 1H).




4H-1,2,9,10-Tetramethoxy-5,6-dihydrobenzo[de,g]quinoline (2e): 62%; yellow crystals; mp 179.5-182 °C (MeOH-ether); IR (Nujol) 3224, 1635, 1597, 1504 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 3.23 (t, $J = 5.6$ Hz, 2H), 3.47 (t, $J = 5.6$ Hz, 2H), 3.91, 3.99, 4.01, 4.02 (each s, each 3H), 6.60 (s, 1H), 6.94 (s, 1H), 6.99 (s, 1H), 9.09 (s, 1H). EIMS m/z (rel. int.) 340 [(M + H)⁺, 25.8], 339 (M⁺, 100), 324 [(M - CH₃)⁺, 55.6], 266 (17.1), 170 (19.7). Anal. Calcd for $\text{C}_{20}\text{H}_{21}\text{NO}_4$: C, 70.78; H, 6.24; N, 4.13. Found; C, 70.95; H, 6.36; N, 3.88.

2,3,9,10-Tetramethoxy-5,6-dihydroindolo[2,1-a]isoquinoline (3e): 3%; deep green crystals; mp 207-208 °C (MeOH-Et₂O) (lit.⁶ mp 199 °C; ⁷ lit. 201-203 °C; ⁸ 202-203 °C; ⁹ 202-204 °C; ¹ 207-208 °C; ^{10,11} 209-210 °C); ^1H NMR (270 MHz, CDCl_3) δ 3.12 (t, $J = 6.6$ Hz, 2H), 3.91, 2.93, 3.96, 3.96 (each s, each 3H), 4.17 (t, $J = 6.6$ Hz, 2H), 6.64 (s, 1H), 6.75 (s, 1H), 6.80 (s, 1H), 7.07 (s, 1H), 7.17 (s, 1H).



4H-1,2-Dimethoxy-9,10-(methylenedioxy)-5,6-dihydrobenzo[de,g]quinoline (2f): 79%; yellow crystals; mp 185.5-188 °C (MeOH-Et₂O); IR (Nujol) 3346, 1633, 1593, 1492 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 3.23 (t, $J = 5.9$ Hz, 2H), 3.48 (t, $J = 5.9$ Hz, 2H), 3.89, 4.01 (s, each 3H), 6.03 (s, 2H), 6.61 (s, 1H), 6.95 (s, 1H), 7.00 (s, 1H), 8.99 (s, 1H); EIMS m/z (rel. int.) 324 [(M + H)⁺, 21.1], 323 (M⁺, 100), 308 [(M - CH₃)⁺, 31.4], 162 (18.5). Anal. Calcd for $\text{C}_{19}\text{H}_{17}\text{NO}_4$: C, 70.57; H, 5.30; N, 4.33. Found; C, 70.53; H, 5.40; N, 4.13.


2,3-Dimethoxy-9,10-(methylenedioxy)-5,6-dihydroindolo[2,1-a]isoquinoline (3f): 7%; dark green crystals; mp 241-242.5 °C (MeOH-Et₂O); IR (Nujol) 1610, 1549, 1502, 1490 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 3.10 (t, $J = 6.6$ Hz, 2H), 4.12 (t, $J = 6.6$ Hz, 2H), 3.91, 3.95 (s, each 3H), 5.93 (s, 2H), 6.63 (s, 1H), 6.74 (s, 1H), 6.78 (s, 1H), 6.99 (s, 1H), 7.15 (s, 1H); EIMS m/z (rel. int.) 324 [(M + H)⁺, 23.1], 323 (M⁺, 100), 308 [(M - CH₃)⁺, 43.2], 279 (24.0), 162 (22.4). Anal. Calcd for $\text{C}_{19}\text{H}_{17}\text{NO}_4$: C, 70.57; H, 5.30; N, 4.33. Found; C, 70.35; H, 5.41; N, 4.23.



4H-9,10-Dimethoxy-1,2-(methylenedioxy)-5,6-dihydrobenzo[de,g]quinoline (2g): 55%; yellow crystals; mp 182-186 °C (MeOH-Et₂O); IR (Nujol) 1633, 1604, 1487 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 3.20 (t, $J = 5.6$ Hz, 2H), 3.47 (t, $J = 5.9$ Hz, 2H), 3.99,


4.02 (s, each 3H), 6.20 (s, 2H), 6.57 (s, 1H), 6.92 (s, 1H), 6.95 (s, 1H), 8.41 (s, 1H); EIMS m/z (rel. int.) 324 [(M + H)⁺, 24.62], 323 (M⁺, 100), 308 [(M - CH₃), 74.7], 279 (13.0), 162 (20.7). Anal. Calcd for C₁₉H₁₇NO₄: C, 70.57; H, 5.30; N, 4.33. Found; C, 70.66; H, 5.34; N, 4.15.

9,10-Dimethoxy-2,3-(methylenedioxy)-5,6-dihydroindolo[2,1-*a*]isoquinoline (3g): 7%; dark green crystals; mp 212-216 °C (MeOH-Et₂O); IR (Nujol) 1599, 1550, 1503, 1475 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.09 (t, *J* = 6.3 Hz, 2H), 4.14 (t, *J* = 6.3 Hz, 2H), 3.93, 3.96 (s, each 3H), 5.96 (s, 2H), 6.60 (s, 1H), 6.72 (s, 1H), 6.79 (s, 1H), 7.06 (s, 1H), 7.15 (s, 1H); EIMS m/z (rel. int.): 324 [(M + 1)⁺, 24.09], 323 (M⁺, 100), 308 [(M - CH₃)⁺, 64.7], 280 (16.0), 162 (27.4). Anal. Calcd for C₁₉H₁₇NO₄: C, 70.57; H, 5.30; N, 4.33. Found; C, 70.66; H, 5.38; N, 4.38.




4H-1,2:9,10-Bis(methylenedioxy)-5,6-dihydrodibenzo[*de, g*]quinoline (2h): 45%; yellow crystals; mp 204-207 °C (MeOH-Et₂O); IR (Nujol) 3368, 1632, 1599, 1510 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.20 (t, *J* = 5.9 Hz, 2H), 3.47 (t, *J* = 5.9 Hz, 2H), 6.02, 6.19 (s, each 2H), 6.56 (s, 1H), 6.92 (s, 1H), 6.95 (s, 1H), 8.40 (s, 1H); EIMS m/z (rel. int.) 308 [(M + H)⁺, 23.5], 307 (M⁺, 100), 249 (12.3), 154 (15.1). Anal. Calcd for C₁₈H₁₃NO₄: C, 70.35; H, 4.26; N, 4.56. Found; C, 70.49; H, 4.41; N, 4.49.

2,3:9,10-Bis(methylenedioxy)-5,6-dihydroindolo[2,1-*a*]isoquinoline (3h): 7%; deep green crystals; mp 219.5-222.5 °C (MeOH-Et₂O) (lit.¹ mp 214.5-217.5 °C); ¹H NMR (270 MHz, CDCl₃) δ 3.07 (t, *J* = 6.6 Hz, 2H), 4.09 (t, *J* = 6.6 Hz, 2H), 5.93, 5.96 (s, each 2H), 6.59 (s, 1H), 6.71 (s, 1H), 6.77 (s, 1H), 6.98 (s, 1H), 7.12 (s, 1H).




4H-1,2-Dimethoxy-5,6-dihydrodibenzo[*de, g*]quinoline (2i): 48%; yellow crystals; mp 144-146 °C (MeOH-CH₂Cl₂); IR (Nujol) 3370, 1625, 1595, 1527, 1508 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.27 (t, *J* = 5.9 Hz, 2H), 3.51 (t, *J* = 5.9 Hz, 2H), 3.91, 4.02 (s, each 3H), 6.76 (s, 1H), 7.06 (s, 1H), 7.38 (dt, *J* = 6.9, 6.9, 1.3 Hz, 1H), 7.45 (dt, *J* = 7.9, 7.9, 1.3 Hz, 1H), 7.57 (dd, *J* = 7.9, 1.3 Hz, 1H), 9.48 (d, *J* = 8.3 Hz, 1H); EIMS m/z (rel. int.) 279 (M⁺, 100), 264 [(M - CH₃)⁺, 39.7]. Anal. Calcd for C₁₈H₁₇NO₂: C, 77.40; H, 6.13; N, 5.01. Found; C, 77.38; H, 6.13; N, 4.86.


9,10-Dimethoxy-5,6-dihydroindolo[2,1-*a*]isoquinoline (3i): 3%; deep green crystals; mp 177.5-179.5 °C (MeOH-CH₂Cl₂); IR (Nujol) 1607, 1505 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.12 (t, *J* = 6.6 Hz, 2H), 4.22 (t, *J* = 6.6 Hz, 2H), 3.91, 3.96 (each s, each 3H), 6.75 (s, 1H), 6.76 (s, 1H), 7.06-7.21 (m, 2H), 7.24 (s, 1H), 7.31 (d, *J* = 7.9 Hz, 1H), 7.61 (d, *J* = 7.9 Hz, 1H); EI-MS m/z (rel. int.) 280 [(M + H)⁺, 23.45], 279 (M⁺, 100), 264 [(M - CH₃)⁺, 22.8], 236 (23.7), 221 (10.5), 204 (8.4), 192 (12.0), 140 (14.3). Anal. Calcd for C₁₈H₁₇NO₂: C, 77.40; H, 6.13; N, 5.01. Found; C, 77.49; H, 6.14; N, 4.99.




Lysicamine (6): mp 203-205 °C dec (MeOH-hexane) (lit.¹² mp 210-211 °C); ¹H NMR (270 MHz, CDCl₃) δ 4.02 (s, 3H), 4.11 (s, 3H), 7.23 (s, 1H), 7.58 (ddd, *J* = 8.3, 7.9, 1.0 Hz, 1H), 7.74-7.81 (m, 2H), 8.59 (dd, *J* = 7.9, 1.7 Hz, 1H), 8.9 (d, *J* = 5.3 Hz, 1H), 9.20 (d, *J* = 8.3 Hz, 1H).




1-(Benzoyl)-6,7-dimethoxy-2,3-dihydroisoquinoline (7): a colorless oil;¹³ ¹H NMR (270 MHz, CDCl₃) δ 2.82 (t, *J* = 7.6 Hz, 2H), 3.78 (s, 3H), 3.92 (t, *J* = 7.6 Hz, 2H), 3.93 (s, 3H), 6.76 (s, 1H), 7.44-7.50 (m, 2H), 8.02-8.06 (m, 2H).




1-[(2'-Bromophenyl)hydroxymethyl]-6,7-dimethoxyisoquinoline (9): prepared by treatment of the compound **8** with NaBH₄; colorless crystals (98 %); mp 143-145 °C (benzene-hexane); IR (Nujol) 3744-3370, 1510 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 3.88, 3.99 (each s, each 3H), 6.71 (s, 1H), 6.88-6.93 (m, 1H), 7.05-7.13 (m, 4H), 7.54 (d, *J* = 5.6 Hz, 1H), 7.61-7.64 (m, 1H), 8.41 (d, *J* = 5.6 Hz, 1H). EI-MS *m/z* (rel. int.) 373 (M⁺, 14), 294 [(M - Br)⁺, 100], 278 (12), 262 (5). Anal. Calcd for C₁₈H₂₀NO₃Br; C, 57.77; H, 4.31; N, 3.74; Br, 21.35. Found; C, 57.65; H, 4.23; N, 3.87; Br, 21.27.




1-[(phenyl)hydroxymethyl]-6,7-dimethoxyisoquinoline (10): colorless crystals; mp 130-131 °C (MeOH-Et₂O) (lit.¹³ mp 140 °C); ¹H NMR (270 MHz, CDCl₃) δ 3.78, 3.98, (each s, each 3H), 6.18, 7.06, 7.07 (each s, each 1H), 7.22-7.36 (m, 5H), 7.50, 8.40 (each d, *J* = 6.6 Hz, each 1H).




(±)-Nuciferine (12a-5): 27%; colorless crystals; mp 135-136 °C (hexane) (lit.¹⁴ mp 134.5-135.5 °C; ¹⁵ 136-137 °C); ¹H NMR (270 MHz, CDCl₃) δ 2.44-2.72 (m, 3H), 2.55 (s, 3H), 3.00-3.21 (m, 4H), 3.65 (m, 3H), 3.88 (s, 3H), 6.63 (s, 1H), 7.22-7.36 (m, 2H), 8.53 (d, *J* = 8.0 Hz, 1H).




(±)-Roemerine (12a-2): a colorless oil (35%); IR (neat) 1503 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 2.44-2.74 (m, 3H), 2.56 (s, 3H), 3.02-3.20 (m, 4H), 5.93, 6.08 (each d, $J = 1.7$ Hz, each 1H), 6.56 (s, 1H), 7.22-7.34 (m, 2H), 8.08 (d, $J = 8.0$ Hz, 1H); EIMS m/z (rel. int.) 279 (M^+ , 100), 236 (62), 190 (93); HRMS Calcd for $\text{C}_{18}\text{H}_{17}\text{NO}_2$: 279.1253. Found; 279.1259.




(±)-Glaucine (12a-3): 24%; light yellow crystals; mp 132-133°C (MeOH- Et_2O) (lit. ¹⁶ mp 118-120 °C); ^1H NMR (270MHz, CDCl_3) δ 2.46~2.71 (m, 4H), 2.55 (s, 3H), 2.99-3.17 (m, 3H), 3.65, 3.89, 3.90, 3.93 (each s, each 3H), 6.59, 6.78, 8.09 (each s, each 1H).




(±)-Neolitsine (12a-4): 22%; colorless crystals; mp 137-8°C (Et_2O -hexane) (lit. ¹⁷ mp 193-195 °C); ^1H NMR (270MHz, CDCl_3) δ 2.45-2.66 (m, 3H), 2.53 (s, 3H), 3.00-3.16 (m, 3H), 3.00-3.16 (m, 4H), 5.92, 6.05 (AB type, $J = 1.3$ Hz, each 1H), 5.95, 5.97 (AB type, $J = 1.3$ Hz, each 1H), 6.52, 6.75, 7.61 (s, 1H).




4H-6-Acetyl-1,2,9,10-tetramethoxy-5,6,6a,7-tetrahydrodibenzo[de,g]quinoline (12a-5): 25%; a colorless oil; IR (neat) 1641, 1515 cm^{-1} ; ^1H NMR (270MHz, CDCl_3) δ 2.19, 2.23 (each s, 2:3, 3 H), 2.63-3.12 (m, 5H), 3.26-3.32 (m, 0.6H), 3.67 (s, 3H, s), 3.90-3.94 (m, 9H), 4.54-4.60 (m, 0.4 H), 4.40-4.99 (m, 0.4 H), 5.05-5.12 (m, 0.6 H), 6.65 (s, 0.6H), 6.67 (s, 0.4 H), 6.79 (br, s, 1H), 8.15 (s, 0.6 H), 8.18 (s, 0.4 H); EIMS m/z (rel. int.) 383 (M^+ , 80), 311 [($\text{M} - \text{CH}_2\text{Nac}$) $^+$, 100]. HRMS calcd for $\text{C}_{22}\text{H}_{26}\text{NO}_5$ 383.1730, found 389.1733.




4H-6-Benzyl-1,2,9,10-tetramethoxy-5,6,6a,7-tetrahydrodibenzo[de, g]quinoline (12a-6): 33%; colorless crystals; mp 161-163°C (MeOH-Et₂O); IR (Nujol) 1515 cm⁻¹; ¹H NMR (270MHz, CDCl₃) δ 2.30-2.56 (m, 1H), 2.63-2.65 (m, 2H), 2.73 (d, *J* = 13.5 Hz, 1H), 2.94-3.17 (m, 3H), 3.30-3.38 (m, 2H), 2.88, 3.65, 3.91, 3.94 (each s, each 3H), 4.54-4.60 (m, 0.4 H), 4.37 (d, *J* = 13.5 Hz, 1H), 6.59, 6.79 (each s, each 1H), 7.28-7.65 (m, 5H), 8.09 (s, 1H); EIMS *m/z* (rel. int.) 431 (M⁺, 71.0), 416 [(M - CH₃)⁺, 52.0], 352 [(M - C₆H₅CH₂)⁺, 18.0], 91 (100). HRMS calcd for C₂₇H₂₉NO₄ 431.2081, found 431.2096. Anal. Calcd for C₂₇H₂₉NO₄: C, 75.15; H, 6.77; N, 3.25. Found: C, 75.31; H, 6.87; N, 3.29.




4H-6-Carboethoxy-1,2,9,10-tetramethoxy-5,6,6a,7-tetrahydrodibenzo[de, g]quinoline (12b): 50%; colorless crystals; mp 166-168 °C (MeOH) (lit. ¹⁸ mp 124-125 °C; ¹⁹ 143-144 °C); ¹H NMR (270MHz, CDCl₃) δ 1.29 (t, *J* = 6.9 Hz, 3H), 2.61-3.05 (m, 5 H), 3.66, 3.90, 3.91, 3.93 (each s, each 3H), 4.22 (q, *J* = 6.9 Hz, 2H), 4.45 (br, d, *J* = 10.5 Hz, 1H), 4.74 (dd, *J* = 13.2, 4.6 Hz, 1H), 6.64, 6.78, 8.16 (each s, each 1H).




(±)-*trans*-7-Hydroxynuciferine (12c-1): 67%; colorless crystals; mp 140-142°C (Et₂O-MeOH); IR (Nujol) 3612-3004, 1599, 1499 cm⁻¹; ¹H NMR (270MHz, CDCl₃) δ 2.59 (m, 3H), 2.67-2.73 (m, 2H), 3.05-3.16 (d, *J* = 2.0 Hz, 1H), 3.67, 3.89 (each s, each 3H), 4.81 (d, *J* = 2.6 Hz, 1H), 6.64 (s, 1H), 7.30-7.33 (m, 1H), 7.40-7.89 (s, 2H), 8.48 (d, *J* = 8.9 Hz, 1H); EIMS *m/z* (rel. int.) 311 (M⁺, 70), 293 [(M - H₂O)⁺, 85], 280 [(M - MeOH)⁺, 85], 91 (00). HRMS calcd for C₁₉H₂₁NO₃ 311.1531, found 311.1521.




(±)-Ushinsunine (12c-2): 60 %; colorless crystals; mp 143-145 °C (Et₂O) (lit. ^{19,20} mp 144-145°C); ¹H NMR (270MHz, CDCl₃) δ 2.60 (m, 3H), 2.62-2.75 (m, 2H), 3.06-3.16 (m, 2H), 3.72, 4.88 (each d, *J* = 2.3 Hz, each 1H), 5.93, 6.09 (d, *J* = 1.3 Hz, 1H), 7.27-7.33 (m, 1H), 7.40-7.46 (m, 2H), 8.15 (d, *J* = 8.9 Hz, 1H).



(±)-*trans*-7-Hydroxyglaucine (12c-3): 57%; a colorless oil; IR (neat) 1638, 1598, 1519, 1519 cm^{-1} ; ^1H NMR (270MHz, CDCl_3) δ 2.60 (s, 3H), 2.67-2.74 (m, 2H), 3.06-3.13 (m, 2H), 3.15 (d, $J = 2.6$ Hz, 1H), 3.68, 3.89, 3.93, 3.95 (s, each 3H), 4.76 (d, $J = 2.6$ Hz, 1H), 6.60 (s, 1H), 6.95 (s, 1H), 8.22 (s, 1H); EIMS m/z (rel. int.) 371 (M^+ , 43), 293 [($\text{M} - \text{H}_2\text{O}$) $^+$, 100], 338 [($\text{M} - \text{H}_2\text{O} - \text{CH}_3$) $^+$, 66], 91 (100). HRMS Calcd for $\text{C}_{21}\text{H}_{25}\text{NO}_5$: 371.1762, found; 371.1732.



(±)-*trans*-7-Hydroxyneolitsine (12c-4): 68 %; colorless crystals; mp 150-152°C; IR (neat) 1662, 1629, 1585, 1559, 1525, 1510 cm^{-1} ; ^1H NMR (270MHz, CDCl_3) δ 2.58 (s, 3H), 2.63-2.73 (m, 2H), 3.03-3.16 (m, 2H), 3.21 (d, $J = 2.7$ Hz, 1H), 4.75 (d, $J = 2.7$ Hz, 1H), 5.92, 6.60 (AB type, $J = 1.7$ Hz, each 1H), 5.98, 6.00 (AB type, $J = 1.7$ Hz, each 1H), 6.52 (s, 1H), 6.91 (s, 1H), 7.70 (s, 1H); EIMS m/z (rel. int.) 339 (M^+ , 100), 321 [($\text{M} - \text{H}_2\text{O}$) $^+$, 63.4], 310 (17.8), 296 (50.2), 280 (24), 190 (76.9). Anal. Calcd for $\text{C}_{19}\text{H}_{17}\text{NO}_5$: C, 67.25; H, 5.05; N, 4.13. Found: C, 67.37; H, 5.20; N, 4.06.



(±)-*trans*-4H-1,2-Dimethoxy-7-hydroxy-9,10-(methylenedioxy)-5,6,6a,7-tetrahydrodibenzo[de, g]quinoline (18c): 14 %; a colorless oil; IR (Nujol) 3710-3072, 1609, 1509 cm^{-1} ; ^1H NMR (270MHz, CDCl_3) δ 2.61-2.72 (m, 2H), 2.88-3.18 (m, 2H), 3.37-3.48 (m, 1H), 3.70 (s, 3H), 3.88 (s, 3H), 4.42 (d, $J = 3.0$ Hz, 1H), 6.00 (d, $J = 1.0$ Hz, 2H), 6.63, 6.87, 8.07 (each s, each 1H); EIMS m/z (rel. int.) 341 (M^+ , 38), 323 [($\text{M} - \text{H}_2\text{O}$) $^+$, 100], 310 (47), (17), 296 (50), 280 (17), 190 (76). HRMS calcd for $\text{C}_{19}\text{H}_{19}\text{NO}_5$ 341.1251, found 341.1263.

References

- (1) For preparation of 1-(2'-bromobenzyl)-3,4-dihydroisoquinolines, see: Orito, K.; Miyazawa, M.; Kanbayashi, R.; Tokuda, M.; Suginome, H. *J. Org. Chem.* **1999**, *64*, 6583-6596.
- (2) Cava, M. P.; Venkateswarlu, M.; Srinivasan, M.; Edie, D. L. *Tetrahedron* **1972**, *28*, 4299-4307.
- (3) Ito, K.; Furukawa, H. *Tetrahedron Lett.* **1970**, *34*, 3023-3024.
- (4) Lahey, F. N.; Max, K. F. *Aust. J. Chem.* **1971**, *24*, 671-672.
- (5) Cava, M. P.; Venkateswarlu, M. *Tetrahedron* **1971**, *27*, 2639-2643.
- (6) Ewing, J.; Hughes, G. K.; Ritchie, E.; Taylor, W. C. *Nature* **1952**, *169*, 618-619 and *Aust J. Chem.* **1953**, *6*, 78-85.
- (7) Robinson, R.; Sugasawa, S. *J. Chem. Soc.* **1932**, 798-805.
- (8) Kametani, T.; Shibuya, S.; Kano, S. *J. Chem. Soc. Perkin I* **1973**, 1212-1214.
- (9) Kametani, T.; Ogasawara, K. *J. Chem. Soc. (C)* **1967**, 2208-2212.
- (10) Mak, C. P.; Brossi, A. *Heterocycles* **1979**, *12*, 1413-1416.
- (11) Ambros, R.; von Angerer, S.; Wiegrebe, W. *Arch. Pharm.* **1988**, *321*, 481-486.
- (12) Katsui, N.; Sato, K.; Tobinaga, S. Takeuchi, N.; *Tetrahedron Lett.* **1966**, 6257-6261.
- (13) Mahuzier, G.; Hamon, M. *Bull. Soc. Chim. France* **1969**, 684-690.
- (14) Cava, M. P.; Michell, M. J.; Havlicek, S. C.; Lindert, A.; Spangler, R. J. *J. Org. Chem.* **1970**, *35*, 175-179.
- (15) Gulland, J. M.; Haworth, R. D. *J. Chem. Soc.* **1928**, 581-591.
- (16) Gupta, S.; Bahakuni, D. S. *Synthetic Commun.* **1989**, *19*, 393-401.
- (17) Tayler, E. C.; Andrade, J. G.; Rall, G. J. H.; McKillop, A. *J. Am. Chem. Soc.* **1980**, *102*, 6513-6519.
- (18) Estévez, J. C.; Villaverde, C. M.; Estévez, R. J.; Castedo, L. *Tetrahedron Lett.* **1991**, *32*, 529-530 and *Tetrahedron* **1994**, *50*, 2107-2114.
- (19) Kessar, S. V.; Gupta, Y. P.; Yadav, V. S.; Nalula, M. Mohammad, T. *Tetrahedron Lett.* **1980**, *21*, 3307-3308.
- (20) Seebach, D.; Huber, I. M. P.; Syfrig, M. A. *Helv. Chim. Acta* **1987**, *70*, 1357-1377.